Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
暂无分享,去创建一个
N. Futran | G. Laramore | J. Liao | U. Parvathaneni | C. Baik | K. Eaton | R. Martins | C. Rodriguez | B. Barber | Q. Wu | J. Voutsinas | C. Chalker | J. Houlton | R. Santana-Davila | Victoria Hwang | Sylvia M. Lee | Q. Wu | Q. Wu | Q. Wu